Risk factors

Silexion focuses heavily on reverse stock splits, Nasdaq listing compliance, and financing dilution risks.

Pandemic risk remains, but COVID-19 is no longer named; impacts include customer liquidity, demand, delivery, supply chains, and mitigation measures.

Telomir faces significant going concern doubts with zero revenues and a reliance on external financing.

Trevi highlights risks around clinical trials for lead candidate Haduvio, shifting regulatory and tax policies, and patent protections.

X4 Pharmaceuticals restructured operations, reducing headcount by 50% in September 2025 to focus on the 4WARD Phase 3 trial for mavorixafor in congenital neutropenia.

Xerox completed the Lexmark acquisition, increasing total debt to $4.2 billion and adding manufacturing complexity.

Share-repurchase amounts and timing are now identified as variable and can be suspended or terminated.

Accumulated deficit grew to $639.9 million as the company remains unprofitable with ongoing net losses.

Alto Neuroscience expanded its risk disclosures following securities class action litigation and a larger federal tax loss carryforward of $78.5 million.

Ampco-Pittsburgh added risks concerning liquidity, corporate reorganizations, international tariffs, and sale-leaseback transactions. Stock listing risks shifted following the expiration of Series A warrants.

Aprea faces clinical trial pauses for ABOYA-119 and ATRN-119, a Nasdaq delisting threat over low share prices, and expanding net deferred tax asset valuations.

Ardent Health faces newly disclosed risks concerning AI implementation challenges and ongoing securities class action and derivative lawsuits. Expiration of ARPA health insurance subsidies at the end of 2025 creates coverage eligibility risks. Revenue concentration in Texas and Oklahoma remains high at 59.3% in 2025.